Advise Saving Nourianz as a Last Resort for Parkinson's

February 2020

Nourianz (NUR-ee-anz, istradefylline) will be the first "adenosine antagonist" for Parkinson's disease.

It's touted as a NON-dopaminergic add-on for "off" episodes...when scheduled carbidopa/levodopa wears off between doses and symptoms (tremor, etc) return, especially as Parkinson's progresses.

But once-daily Nourianz doesn't seem to reduce "off" time more than dopaminergic add-ons...such as COMT inhibitors (entacapone, etc), dopamine agonists (pramipexole, etc), or MAO-B inhibitors (rasagiline, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote